All In Biotech

Drug Trial Radar · NCT06323824

Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.

Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment - A Pragmatic Hybrid Effectiveness/Implementation Trial

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Jun 4, 2024

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institutes of Health (NIH); National Institute on Drug Abuse (NIDA); The Emmes Company, LLC; University of California, San Francisco; Boston Medical Center (BMC); Hennepin Healthcare Research Institute; Alameda Health System; Marshall Health; Kaiser Permanente
First posted
Mar 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to compare the effectiveness of office-based methadone with pharmacy administration and/or dispensing to office-based buprenorphine for the treatment of opioid use disorder. This study will also examine factors influencing the implementation of office-based methadone.

Conditions

  • Opioid Use Disorder

Interventions

  • MethadoneDrug

    Drug: Methadone Possible formulations: 10 and 50 mg tablets

  • Buprenorphine (BUP)Drug

    Drug: Buprenorphine (BUP) Possible formulations: A. Buprenorphine, 225 mcg to 24 mg, 225 mcg to 32 mg per day, B. Buprenorphine (Extended release), 300 mg q 28 days (Sublocade), 100 mg q 28 days (Sublocade), 8 mg q 7 days (Brixadi), 16 mg q 7 days (Brixadi), 24 mg q 7 days (Brixadi), 32 mg q 7 days (Brixadi), 64 mg q 28 days (Brixadi), 96 mg q 28 days (Brixadi), 128 mg q 28 days (Brixadi),

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of days of continuous treatment with site clinician-prescribed methadone or buprenorphine, as randomized, during the 168 days post-randomization among RCT participants.Time frame: up to Day 168

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Highland Hospital Bridge Clinic at Alameda Health System

    Oakland, California · Recruiting

  • Outpatient Buprenorphine Induction Clinic, University of California, San Francisco

    San Francisco, California · Recruiting

  • Rapid Start Clinic, Kaiser Permanente Colorado

    Denver, Colorado · Recruiting

  • Officed Based Addiction Treatment Program, Boston Medical Center

    Boston, Massachusetts · Recruiting

  • Hennepin Healthcare Addiction Medicine

    Minneapolis, Minnesota · Recruiting

  • Marshall University Division of Addiction Sciences P.R.O.A.C.T

    Huntington, West Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.